Medical Necessity of Infliximab for Crohn's Disease

Assessment of Medical Necessity

• Infliximab (Inflectra) at a dose of 10 mg/kg every 8 weeks is medically necessary for the treatment of Crohn's disease in patients who have achieved disease control with this dosage regimen and have documented intestinal strictures, as recommended by clinical guidelines 1, 2

Dosing Considerations

• Standard maintenance dosing for Crohn's disease is 5 mg/kg every 8 weeks, according to the Journal of Crohn's and Colitis 3

Continuation Criteria Assessment

• The presence of intestinal strictures on colonoscopy demonstrates objective evidence of disease that requires ongoing treatment, as supported by Gut 4

Combination Therapy

• Consider combination therapy with a thiopurine for at least 6-12 months to improve efficacy and reduce immunogenicity, as recommended by the Journal of Crohn's and Colitis and Gut 4, 5

Monitoring and Optimization

• Regular monitoring of drug levels may help optimize dosing and predict response to therapy, according to the Journal of Crohn's and Colitis 6